# Repligen Corp (RGEN)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/repligen-corp/ JSON: https://steadybase.io/company/repligen-corp.json Checked Nov 10, 2026. Latest filing read: Oct 30, 2026.

## Company

- Legal name: REPLIGEN CORP
- Ticker: RGEN (Nasdaq)
- SEC CIK: 0000730272
- Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
- Headquarters: Waltham, MA
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: repligen.com
- LinkedIn: https://www.linkedin.com/company/repligen-corporation
- Next earnings date: Jan 26, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $738.3M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/0001193125-26-076528-index.html
- Operating income: $55.2M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/0001193125-26-076528-index.html
- Net income: $48.9M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/0001193125-26-076528-index.html
- SG&A: $290.5M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/0001193125-26-076528-index.html
- Employees: 2,000 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/rgen-20251231.htm
- Shares outstanding: 63,923,738 as of Oct 23, 2026 (10-Q filed Oct 30, 2026). Source: https://www.sec.gov/Archives/edgar/data/730272/000162828026068562/0001628280-26-068562-index.html
- Auditor: Ernst & Young LLP, Boston, Massachusetts, United States, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/rgen-20251231.htm

## Business

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/rgen-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $738.3M | $55.2M | $48.9M | $290.5M |
| Dec 31, 2024 | $634.4M | -$35.1M | -$25.5M | $263.4M |
| Dec 31, 2023 | $632.4M | $47.7M | $35.6M | $218.6M |
| Dec 31, 2022 | $801.5M | $224.7M | $186.0M | $215.8M |
| Dec 31, 2021 | $670.5M | $167.2M | $128.3M | $183.9M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/repligen-corp.json

## Officers and directors

- Olivier Loeillot, Chief Executive Officer. LinkedIn: https://linkedin.com/in/olivierloeillot. Source: Form 4 filed Sep 25, 2026, https://www.sec.gov/Archives/edgar/data/730272/000162828026063572/0001628280-26-063572-index.htm
- Jason K. Garland, CFO. LinkedIn: https://www.linkedin.com/in/jason-garland-73b72210. Source: Form 4 filed Sep 28, 2026, https://www.sec.gov/Archives/edgar/data/730272/000162828026063714/0001628280-26-063714-index.htm
- James Bylund, Chief Operating Officer. LinkedIn: https://linkedin.com/in/james-bylund-82758314. Source: Form 4 filed Mar 23, 2026, https://www.sec.gov/Archives/edgar/data/730272/000119312526119034/0001193125-26-119034-index.htm
- Violetta Hughes, CHIEF ACCOUNTING OFFICER. LinkedIn: https://linkedin.com/in/violetta-hughes-73998a58. Source: Form 4 filed Sep 2, 2026, https://www.sec.gov/Archives/edgar/data/730272/000162828026060105/0001628280-26-060105-index.htm
- Brian Robb Douglass, CHIEF PRODUCT OFFICER. Source: Form 4 filed May 8, 2026, https://www.sec.gov/Archives/edgar/data/730272/000119312526214265/0001193125-26-214265-index.htm
- Tony J. Hunt, Executive Chair of the Board. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/rgen-20251231.htm
- Ralf Kuriyel, Senior VP, R&D. LinkedIn: https://linkedin.com/in/ralf-kuriyel-38656011. Source: Form 4 filed Mar 23, 2026, https://www.sec.gov/Archives/edgar/data/730272/000119312526119047/0001193125-26-119047-index.htm
- Carrie Eglinton Manner, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/rgen-20251231.htm
- Glenn P. Muir, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/rgen-20251231.htm
- Karen Dawes, Lead Independent Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/rgen-20251231.htm
- Konstantin Konstantinov, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/rgen-20251231.htm
- Margaret A. Pax, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/rgen-20251231.htm
- Martin D. Madaus, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/rgen-20251231.htm
- Nicolas M. Barthelemy, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/rgen-20251231.htm
- Rohin Mhatre, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/rgen-20251231.htm
- Brian Douglass, Named in proxy. LinkedIn: https://linkedin.com/in/brian-douglass-4100513. Source: DEF 14A filed Apr 2, 2026, https://www.sec.gov/Archives/edgar/data/730272/000119312526140115/rgen-20260402.htm
- Konstantin Konstantinov, Ph.D., Board member (per proxy). Source: DEF 14A filed Apr 2, 2026, https://www.sec.gov/Archives/edgar/data/730272/000119312526140115/rgen-20260402.htm
- Martin Madaus, D.V.M., Ph.D., Board member (per proxy). Source: DEF 14A filed Apr 2, 2026, https://www.sec.gov/Archives/edgar/data/730272/000119312526140115/rgen-20260402.htm
- Rohin Mhatre, Ph.D., Board member (per proxy). Source: DEF 14A filed Apr 2, 2026, https://www.sec.gov/Archives/edgar/data/730272/000119312526140115/rgen-20260402.htm

## Recent 8-K events

- Nov 6, 2026: Item 1.01, Entry into a material definitive agreement; Item 2.03, Creation of a direct financial obligation; Item 3.02, Unregistered sales of equity securities; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/730272/000162828026071650/rgen-20261106.htm
- Oct 30, 2026: Item 3.02, Unregistered sales of equity securities; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/730272/000162828026068382/rgen-20261029.htm
- Oct 27, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/730272/000162828026067405/rgen-20261027.htm
- Oct 6, 2026: Item 2.01, Completion of acquisition or disposition of assets; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/730272/000119312526415015/d240327d8k.htm
- Sep 15, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/730272/000162828026062043/rgen-20260910.htm
- Sep 8, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/730272/000119312526385380/d131600d8k.htm
- Jul 28, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/730272/000119312526318853/rgen-20260728.htm
- Jul 22, 2026: Item 1.01, Entry into a material definitive agreement; Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/730272/000119312526311402/d141685d8k.htm
- May 15, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/730272/000119312526225380/rgen-20260514.htm
- May 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/730272/000119312526205011/rgen-20260505.htm

## Insider trades (Form 4)

- Oct 5, 2026: Olivier Loeillot (Chief Executive Officer) sold 5,535 shares, about $1.0M. Source: https://www.sec.gov/Archives/edgar/data/730272/000162828026065238/0001628280-26-065238-index.htm
- Sep 24, 2026: Olivier Loeillot (Chief Executive Officer) sold 12,946 shares, about $2.5M. Source: https://www.sec.gov/Archives/edgar/data/730272/000162828026063572/0001628280-26-063572-index.htm
- Sep 21, 2026: Olivier Loeillot (Chief Executive Officer) sold 5,426 shares, about $976,680. Source: https://www.sec.gov/Archives/edgar/data/730272/000162828026063026/0001628280-26-063026-index.htm
- Sep 4, 2026: Olivier Loeillot (Chief Executive Officer) sold 3,035 shares, about $503,507. Source: https://www.sec.gov/Archives/edgar/data/730272/000162828026060911/0001628280-26-060911-index.htm
- Aug 20, 2026: Olivier Loeillot (Chief Executive Officer) sold 5,426 shares, about $976,680. Source: https://www.sec.gov/Archives/edgar/data/730272/000162828026058417/0001628280-26-058417-index.htm
- Jul 16, 2026: Jason K. Garland (CFO) sold 530 shares, about $79,500. Source: https://www.sec.gov/Archives/edgar/data/730272/000119312526307925/0001193125-26-307925-index.htm
- Jun 25, 2026: Jason K. Garland (CFO) sold 733 shares, about $106,285. Source: https://www.sec.gov/Archives/edgar/data/730272/000119312526285449/0001193125-26-285449-index.htm
- Apr 21, 2026: Olivier Loeillot (Chief Executive Officer) sold 3,832 shares, about $536,480. Source: https://www.sec.gov/Archives/edgar/data/730272/000119312526169682/0001193125-26-169682-index.htm
- Dec 17, 2025: Karen A. Dawes (Director) sold 275 shares, about $44,275. Source: https://www.sec.gov/Archives/edgar/data/730272/000119312525324912/0001193125-25-324912-index.htm
- Nov 25, 2025: Olivier Loeillot (Chief Executive Officer) sold 7,041 shares, about $1.2M. Source: https://www.sec.gov/Archives/edgar/data/730272/000119312525300642/0001193125-25-300642-index.htm
- Nov 18, 2025: James Bylund (Chief Operating Officer) sold 2,191 shares, about $331,301. Source: https://www.sec.gov/Archives/edgar/data/730272/000119312525288160/0001193125-25-288160-index.htm
- Nov 13, 2025: Anthony Hunt (Director) sold 20,000 shares, about $3.1M. Source: https://www.sec.gov/Archives/edgar/data/730272/000119312525283092/0001193125-25-283092-index.htm
- Nov 12, 2025: Anthony Hunt (Director) sold 25,000 shares, about $3.9M. Source: https://www.sec.gov/Archives/edgar/data/730272/000119312525280266/0001193125-25-280266-index.htm
- Sep 10, 2025: Anthony Hunt (Director) sold 29,111 shares, about $3.5M. Source: https://www.sec.gov/Archives/edgar/data/730272/000119312525201224/0001193125-25-201224-index.htm
- Aug 8, 2025: Martin D. Madaus (Director) bought 1,800 shares, about $201,834. Source: https://www.sec.gov/Archives/edgar/data/730272/000095017025107084/0000950170-25-107084-index.htm

## Latest filings

- 8-K filed Oct 30, 2026: https://www.sec.gov/Archives/edgar/data/730272/000162828026068382/rgen-20261029.htm
- 10-K filed Feb 26, 2026: https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/rgen-20251231.htm
- 10-Q filed Oct 30, 2026: https://www.sec.gov/Archives/edgar/data/730272/000162828026068562/rgen-20260930.htm
- DEF 14A filed Apr 2, 2026: https://www.sec.gov/Archives/edgar/data/730272/000119312526140115/rgen-20260402.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/